Long-term clinical outcome with titanium-nitride-oxide-coated stents and paclitaxel-eluting stents for coronary revascularization in an unselected population.
BACKGROUND
The aim of this study was to evaluate long-term clinical events in patients treated with titanium-nitride-oxide-coated bio-active stents (BAS) and paclitaxel-eluting stents (PES) in routine clinical practice.


METHODS
All patients undergoing percutaneous coronary intervention (PCI) were eligible for this single-centre registry between May 2003 and November 2004. The primary end point of the study was major adverse cardiac events (MACE) at 3 years including myocardial infarction (MI), cardiac death and target vessel revascularization (TVR).


RESULTS
A total of 201 patients received BAS and 204 patients PES. In addition, during the same study period, 184 patients were treated with bare-metal stents (BMS) and 125 patients underwent CABG. Complete follow-up datasets were available in all patients. After 3 years of follow-up, the rate of MACE was 13.9% for BAS and 23.5% for PES (adjusted HR 2.0, 95% CI 1.2-3.2, p=0.006). This difference was mainly driven by a higher incidence of MI in the PES group (19.1%) compared with the BAS (7.5%) group (adjusted HR 3.2, 95% CI 1.7-5.8, p<0.001). The rate of MACE was 31.5% in the BMS group and 4% in the CABG group. At 3 years, stent thrombosis occurred in 15 patients in the PES (7.4%) group. There was no stent thrombosis in the BAS group.


CONCLUSIONS
After the 3 year follow-up, BAS resulted in better long-term outcome compared with PES with infrequent need for TVR.
Karjalainen
Pasi P
PP
Department of Cardiology, Satakunta Central Hospital, Sairaalantie 3, FIN-28100, Pori, Finland. pasi.karjalainen@satshp.fi
Annala
Antti-Pekka
AP
Ylitalo
Antti
A
Vahlberg
Tero
T
Airaksinen
K E Juhani
KE
D000497:Alloys; D000972:Antineoplastic Agents, Phytogenic / Q000494:pharmacology; D020099:Coated Materials, Biocompatible; D054855:Drug-Eluting Stents; D005500:Follow-Up Studies; D006801:Humans; D017202:Myocardial Ischemia / Q000601:surgery*; D009204:Myocardial Revascularization / Q000379:methods*; D017239:Paclitaxel / Q000494:pharmacology*; D018579:Patient Selection; D011446:Prospective Studies; D011474:Prosthesis Design; D012042:Registries; D055502:Secondary Prevention; D013997:Time Factors; D014025:Titanium; D016896:Treatment Outcome
D000497:Alloys; D000972:Antineoplastic Agents, Phytogenic; D020099:Coated Materials, Biocompatible; C434243:titanium-nitride-oxide; D014025:Titanium; D017239:Paclitaxel